Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Neoadjuvant Cemiplimab in Stage I-II Merkel Cell Carcinoma: Safety and Biomarker Analysis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04975152
Recruitment Status : Recruiting
First Posted : July 23, 2021
Last Update Posted : August 5, 2021
Sponsor:
Collaborators:
Regeneron Pharmaceuticals
Sanofi-Synthelabo
Information provided by (Responsible Party):
H. Lee Moffitt Cancer Center and Research Institute

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : July 2023
Estimated Study Completion Date : July 2026